Yes, regular monitoring is essential, including kidney function tests at baseline and at least annually (more frequently if eGFR is below 60), liver function tests, and HbA1c if you have diabetes
Survodutide: glucagon and GLP-1 pathway research compound
2.2.2 Type II cells Although they are a relatively small subpopulation (only about 19-25% of all TRCs), they might be considered as the key receptor cells
What the Latest Clinical Trial Results Show According to publicly reported late-stage trial data: Participants receiving higher doses achieved average weight loss approaching 2530% over approximately 68 weeks Some individuals lost more than 70 pounds during the study period Participants with obesity and knee osteoarthritis also reported significant reductions in joint pain These outcomes exceeded the average weight loss typically reported in clinical trials of currently approved GLP-1 medications
Potential Side Effects Common side effects include nausea, diarrhea, vomiting, constipation, and abdominal pain
Its not a situation where you max out medications and then consider surgery its tailored to the patient.